Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00381173 · ClinicalTrials.gov registry record · Phase 1

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

A Phase 1 study, sponsored by Eisai.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT00381173 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00381173, a Phase 1 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).

Interventions

  • DRUG Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2006-11
Est. Completion 2008-10
Phase Phase 1

Sponsor

Eisai

287 total trials

What the Registry Record Tells You About NCT00381173

The ClinicalTrials.gov registry entry for NCT00381173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) is the first listed.

NCT00381173 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00381173 about?

NCT00381173 is a clinical study titled "A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing". The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).

What is the current status of trial NCT00381173?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-11. Estimated completion is 2008-10.

What interventions are being tested in trial NCT00381173?

The interventions under investigation include: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) (DRUG).

Who is sponsoring clinical trial NCT00381173?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.